Creating Dengue Virus Mutants for Vaccine Development
Author Information
Author(s): Katherine M. Smith, Kavita Nanda, Carla J. Spears, Mariana Ribeiro, Ricardo Vancini, Amanda Piper, Gwynneth S. Thomas, Malcolm E. Thomas, Dennis T. Brown, Raquel Hernandez
Primary Institution: Arbovax, Incorporated
Hypothesis
Can host-range mutants of Dengue virus be constructed by generating deletions in the transmembrane domain of the E glycoprotein?
Conclusion
The study successfully created novel host-range mutants of Dengue virus that grow preferentially in insect cells and may serve as potential vaccine candidates.
Supporting Evidence
- Mutants were created by deleting specific amino acids in the transmembrane domain of the E glycoprotein.
- These mutants showed preferential growth in insect cells and reduced infectivity in mammalian cells.
- Mouse trials indicated that the mutants elicited a higher neutralizing antibody response compared to the wild-type virus.
Takeaway
Scientists made changes to a virus that usually makes people sick so it can grow better in insects instead of humans, which could help make a vaccine.
Methodology
The study involved creating deletion mutants of the Dengue virus E glycoprotein and testing their growth in insect and mammalian cells.
Limitations
The study was conducted in a mouse model, which is not the natural host for Dengue virus, potentially limiting the applicability of the results.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website